Zacks Investment Research·Jun 23, 2026
3 Best Low-Beta Stocks to Buy Right Away: LQDA, FLXS & AGXLQDA, FLXS and AGX screen as low-beta stocks with positive price moves, solid trading volume and company-specific growth drivers amid market fears.
Liquidia Corporation(LQDA)Earnings, Financials & Key Ratios
LQDA•NASDAQ
$79.21
Price updated Jul 6, 2026
AboutLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Show more
- Revenue$158M+1031.2%
- EBITDA-$50M+58.1%
- Net Income-$69M+47.1%
- EPS (Diluted)-0.80+51.8%
- Gross Margin91.64%+58.0%
- EBITDA Margin-31.49%+96.3%
- Operating Margin-32.45%+96.3%
- Net Margin-43.53%+95.3%
- ROE-112.97%+46.0%
LQDA Price & Volume
Liquidia Corporation (LQDA) stock price & volume — 10-year historical chart
Loading chart...
Liquidia Achieves Commercial Inflection Through Revenue Scaling
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Accelerating
Profitability:Strong
Financial:Healthy
Cash Flow:Robust
Primary Risk:Patent Litigation and Dilution
Key Thesis Takeaways
- Liquidia has successfully transitioned from a development-stage entity to a commercial-scale operation, evidenced by a revenue surge to $132.9 million in 2026Q1.
- While the company has achieved a robust 46.3% operating margin, investors should monitor the ongoing impact of $9.2 million in quarterly stock-based compensation and the persistent legal risks associated with its intellectual property defense.
- The company's ability to maintain its current 37.8% free cash flow margin will be critical as it navigates the competitive landscape of generic treprostinil distribution.
Verdict Logic
the company has demonstrated a fundamental shift toward profitability with a 2026Q1 net income of $52.9 million, suggesting that the current forward P/E of 23.71 may offer value if the current growth trajectory persists.
LQDA Growth Metrics
Liquidia Corporation (LQDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years192.49%
3 Years114.98%
TTM1936.66%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM117.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM108.86%
Return on Capital
10 Years-89.1%
5 Years-50.82%
3 Years-59.26%
Last Year-26.99%
LQDA Recent Earnings
Liquidia Corporation (LQDA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.52+52.9%
$0.34
Rev
$133M+11.2%
$119M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.15+87.5%
$0.08
Rev
$92M+3.9%
$89M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.04+91.1%
$0.45
Rev
$54M-32.7%
$81M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.49-14.0%
$0.43
Rev
$9M-38.2%
$14M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.52vs $0.34+52.9% | $133Mvs $119M+11.2% |
| Q2 2026 | Mar 5, 2026 | $0.15vs $0.08+87.5% | $92Mvs $89M+3.9% |
| Q4 2025 | Nov 3, 2025 | $0.04vs $0.45+91.1% | $54Mvs $81M-32.7% |
| Q3 2025 | Aug 12, 2025 | $0.49vs $0.43-14.0% | $9Mvs $14M-38.2% |
Based on last 12 quarters of dataView full earnings history →
Latest LQDA News
Recent stock market news and headlines for Liquidia Corporation (LQDA)
Seeking Alpha·Jun 16, 2026
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks TranscriptLiquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Fool - Investing News·Jun 15, 2026
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
Peers Comparison
Key metrics vs top competitors for Liquidia Corporation (LQDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $79.21 | $7.04B | -99.01 | 1031.18% | -43.53% | -112.97% | — | |
| $547.25 | $23.23B | 19.64 | 10.61% | 40.61% | 19.24% | — | |
| $4.27 | $1.32B | 213.50 | 22.23% | -6.63% | — | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $111.54 | $24.18B | -17.40 | 66.73% | -144.44% | -130.11% | — |
Compare LQDA vs Peers
Liquidia Corporation (LQDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LQDA SEC Filings & Documents
Liquidia Corporation (LQDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 9, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
5Get notified when LQDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LQDA Frequently Asked Questions
Liquidia Corporation (LQDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Liquidia Corporation's revenue?
Liquidia Corporation (LQDA) reported $288.1M in revenue for fiscal year 2025. This represents a 2080% increase from $13.2M in 2016.
How fast is Liquidia Corporation growing?
Liquidia Corporation (LQDA) grew revenue by 1031.2% over the past year. This is strong growth.
Is LQDA profitable?
Yes, Liquidia Corporation (LQDA) is profitable, generating $22.3M in net income for fiscal year 2025 (-43.5% net margin).
Dividend & Returns
What is LQDA's return on equity?
Liquidia Corporation (LQDA) has a return on equity (ROE) of -113.0%. Negative ROE indicates the company is unprofitable.
What is Liquidia Corporation's free cash flow?
Liquidia Corporation (LQDA) generated $41.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.